Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04865419 · ClinicalTrials.gov registry record · Phase 1
Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT04865419 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 46 participants.
The verdict
NCT04865419, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of the study is to the evaluate safety, tolerability, pharmacokinetics (PK), and efficacy of AZD0466 as monotherapy in partciapants with advanced haematological malignancies and also to assess drug-drug interaction (DDI) potential between AZD0466 and the azole antifungal voriconazole.
Interventions
- DRUG Voriconazole
- DRUG AZD0466
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2023-08-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04865419
The ClinicalTrials.gov registry entry for NCT04865419 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Voriconazole is the first listed.
NCT04865419 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04865419 about?
NCT04865419 is a clinical study titled "Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies". The purpose of the study is to the evaluate safety, tolerability, pharmacokinetics (PK), and efficacy of AZD0466 as monotherapy in partciapants with advanced haematological malignancies and also to assess drug-drug interaction (DDI) potential between AZD0466 and the azole antifungal voriconazole.
What is the current status of trial NCT04865419?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2021-06-11. Estimated completion is 2023-08-08.
What interventions are being tested in trial NCT04865419?
The interventions under investigation include: Voriconazole (DRUG), AZD0466 (DRUG).
Who is sponsoring clinical trial NCT04865419?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.